StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies Reiterates Bullish View on Abbvie (ABBV) Amid 'Double Dose' of Good News
September 7, 2017 1:06 PM
Jefferies analyst Jeffrey Holford reiterated a Buy rating and $94 price target ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
September 11, 2017 8:03 AM
Coherus BioSciences (CHRS) 'Disappointed' in Outcome of '619 IPR Institution Decision
September 7, 2017 11:59 AM
AbbVie (ABBV) Trades at Session High as Biotech Strength Continues, IPR Review Victory
September 7, 2017 11:45 AM
AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year
September 7, 2017 8:57 AM
AbbVie (ABBV) Says Upadacitinib Met Primary Endpoint in Phase 2b Study in Atopic Dermatitis
September 7, 2017 8:05 AM
AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
September 7, 2017 8:03 AM
